Admission to Trading on the OTCQB Venture Market in the United States
RNS & Investor News
First order from leading US weight management brand
15 April 2025
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
products which reduce hunger and food cravings, enhance the gut
microbiome, and sweet fibres as healthy sugar substitutes, announces it
has received its first order from a leading weight management brand in
the United States of America (“USA”).
The order is for SlimBiome® as an ingredient which will be incorporated
into a range of flavoured drinks, similar to SlimBiome Medical, which
reduces hunger. The products will be included in one of the USA's
leading weight management brands. SlimBiome® has undergone multiple
human studies which show its ability to reduce hunger and food cravings
which leads to lower calorie intake. OptiBiotix has been working with
this brand for over 18 months to carry out human studies which allows
the brand to make health claims of hunger control on its products in the
USA. Scientifically substantiated health claims help to differentiate
these products from others on the market. In the changing landscape of
this market, brought about by the anti-obesity drugs, consumers are
actively looking for natural, science backed appetite support products.
SlimBiome® meets this developing trend.
OptiBiotix expect further orders for a second product, a tablet
containing SlimBiome®, within H1 2025. Whilst it is too early to
understand the potential scale of the opportunity, this news is material
in that it represents the inclusion of SlimBiome® in products of one of
the USA's most popular weight management brands. Further information on
the partner and brand will be announced on launch which the Company
anticipates will be in H1 2025. However, the Company reminds investors
that launch timescales are dictated by the brand owner and these can be
subject to change.
Stephen O'Hara, CEO of OptiBiotix Health plc said: “We
are pleased to announce the first order for the use of
SlimBiome® in one of the USA's leading weight management
brands. The use of SlimBiome® has allowed the brand to make health
claims of hunger control on its products which differentiate them
from other products on the market. We anticipate more orders and
product launches with this brand as it extends the range of products
containing SlimBiome® in the USA market in 2025.
“Following the launch of the anti-obesity drugs, natural non-drug
alternatives to reduce hunger and cravings are actively being sought
by consumers. This announcement demonstrates that the science and
multiple human studies carried out on SlimBiome® is now attracting
the interest of major brands around the world.”
The Directors of the Company are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc | www.optibiotix.com | |
Neil Davidson, Chairman | Contact via Walbrook below | |
Stephen O'Hara, Chief Executive | ||
Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
Liam Murray / Jo Turner / Ludovico
Lazzaretti |
||
Peterhouse Capital Limited (Broker) | Tel: 020 7220 9797 | |
Duncan Vasey / Lucy Williams | ||
Walbrook PR Ltd | ||
Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human
microbiome - the collective genome of the microbes in the body - in
order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.Latest Video
OptiBiotix Health PLC - Full Year Results Investor
Presentation
Group CEO Stephen O'Hara | July 2025
Latest Podcast
Stephen OHara interview with Investors
Champion
Stephen O'Hara | 04 Jul 2019
www.investorschampion.com